Valuation: Apogee Therapeutics, Inc.

Market Cap 1.01TCr 878.9Cr 823.9Cr 751.24Cr 1.41TCr 97TCr 1.44TCr 9.7TCr 3.79TCr 48TCr 3.81TCr 3.72TCr 1,61600Cr P/E 2026 *
-28.8x
P/E 2027 * -23.4x
Enterprise Value 953.6Cr 826.58Cr 774.86Cr 706.53Cr 1.33TCr 91TCr 1.35TCr 9.12TCr 3.56TCr 46TCr 3.58TCr 3.5TCr 1,52000Cr EV / Sales 2026 *
-
EV / Sales 2027 * 824x
Free-Float
94.79%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Apogee Therapeutics, Inc.

1 day-0.07%
1 week-0.03%
Current month+0.27%
1 month+0.47%
3 months+60.17%
6 months+98.36%
Current year+78.13%
1 week 134.4
Extreme 134.4
134.72
1 month 133.88
Extreme 133.88
134.88
Current year 60.35
Extreme 60.35
134.88
1 year 35.39
Extreme 35.39
134.88
3 years 14.19
Extreme 14.19
134.88
5 years 14.19
Extreme 14.19
134.88
10 years 14.19
Extreme 14.19
134.88
Manager TitleAgeSince
Chief Executive Officer 36 01/09/2022
Director of Finance/CFO 60 01/01/2023
Chief Tech/Sci/R&D Officer - 01/05/2023
Director TitleAgeSince
Director/Board Member 54 22/06/2023
Director/Board Member 62 01/06/2023
Director/Board Member 36 01/06/2023
Date Insider Type Main position Quantity % Market Cap.
07/08/26
Fairmount Funds Management LLC
Fiscal yearCompany 84,416 0.1507%
07/08/26 Other

Director

0 0%
07/08/26 Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%-0.03%+259.88%+520.44% 1.01TCr
-1.85%-1.50%+2.18%+14.04% 4.92TCr
-1.59%+2.12%+460.02%+573.56% 4.33TCr
-0.85%+7.95%+15.77%+80.09% 4.05TCr
-0.08%+3.91%+26.96%+9.86% 3.98TCr
0.00%+3.59%+20.51%+48.00% 3.27TCr
-3.61%-1.45% - - 1.62TCr
-2.52%-0.52%+24.35%+118.05% 1.62TCr
+1.00%+1.43%+4.86%+22.79% 1.4TCr
-1.09%+5.94%+81.46%+31.15% 1.34TCr
Average -1.12%+2.07%+99.55%+157.55% 2.76TCr
Weighted average by Cap. -1.15%+2.61%+102.58%+149.10%

Financials

2026 *2027 *
Net sales - 1.15Cr 1Cr 93.76L 85.49L 1.61Cr 110.12Cr 1.63Cr 11Cr 4.31Cr 55Cr 4.33Cr 4.24Cr 183.89Cr
Net income -34Cr -30Cr -28Cr -25Cr -48Cr -3.26TCr -48Cr -326.38Cr -127.42Cr -1.63TCr -128.07Cr -125.3Cr -5.44TCr -42Cr -37Cr -34Cr -31Cr -59Cr -4.03TCr -60Cr -404.05Cr -157.74Cr -2.02TCr -158.55Cr -155.11Cr -6.73TCr
Net Debt -60Cr -52Cr -49Cr -45Cr -84Cr -5.76TCr -85Cr -577.45Cr -225.44Cr -2.88TCr -226.59Cr -221.68Cr -9.62TCr -63Cr -55Cr -51Cr -47Cr -88Cr -6.01TCr -89Cr -602.8Cr -235.33Cr -3.01TCr -236.54Cr -231.42Cr -10TCr
Logo Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
Employees
261
Date Price Change Volume
13/26/13 $134.45 -0.07% 12,57,000
12/26/12 $134.55 -0.10% 8,02,271
11/26/11 $134.69 +0.03% 10,60,417
10/26/10 $134.65 -0.14% 7,61,299
07/26/07 $134.84 +0.26% 14,95,196
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
15
Last Close Price
134.45USD
Average target price
134.85USD
Spread / Average Target
+0.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APGE Stock